- Home
- FORR vs ANVS Comparison
FORR vs ANVS Comparison
Compare FORR & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORR | ANVS |
|---|---|---|
| Founded | 1983 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.6M | 111.3M |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FORR | ANVS |
|---|---|---|
| Price | $6.39 | $2.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 193.4K | ★ 313.1K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.92 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.91 | $1.11 |
| 52 Week High | $11.57 | $5.50 |
Technical Indicators
Market Signals| Indicator | FORR | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 46.40 | 44.84 |
| Support Level | $5.02 | $2.27 |
| Resistance Level | $6.71 | $2.63 |
| Average True Range (ATR) | 0.40 | 0.20 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 74.29 | 26.18 |
Price Performance
Historical ComparisonAbout FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.